CRISPR Therapeutics
CRSP
CRSP
411 hedge funds and large institutions have $2.79B invested in CRISPR Therapeutics in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 131 increasing their positions, 127 reducing their positions, and 73 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
13% less capital invested
Capital invested by funds: $3.21B → $2.79B (-$422M)
34% less call options, than puts
Call options by funds: $68.2M | Put options by funds: $103M
40% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 73
Holders
411
Holding in Top 10
5
Calls
$68.2M
Puts
$103M
Top Buyers
| 1 | +$34.9M | |
| 2 | +$28.2M | |
| 3 | +$25M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$17.7M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$11.7M |
Top Sellers
| 1 | -$28.6M | |
| 2 | -$18.7M | |
| 3 | -$13.2M | |
| 4 |
CCM
Cutter Capital Management
New York
|
-$10.9M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$10.1M |